189 related articles for article (PubMed ID: 12427882)
21. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
22. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease.
Jiang Y; Xiao W; Zhang Y; Xing Y
Respirology; 2010 Aug; 15(6):939-46. PubMed ID: 20624254
[TBL] [Abstract][Full Text] [Related]
24. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
26. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
Prostate; 1999 May; 39(2):123-9. PubMed ID: 10221568
[TBL] [Abstract][Full Text] [Related]
27. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
Kwieciński J; Kłak M; Trysberg E; Blennow K; Tarkowski A; Jin T
Arthritis Rheum; 2009 Jul; 60(7):2094-101. PubMed ID: 19565516
[TBL] [Abstract][Full Text] [Related]
28. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
[TBL] [Abstract][Full Text] [Related]
29. Serine proteinase activation in esophageal cancer.
Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
[TBL] [Abstract][Full Text] [Related]
30. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
[TBL] [Abstract][Full Text] [Related]
31. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection.
Roelofs JJ; Rowshani AT; van den Berg JG; Claessen N; Aten J; ten Berge IJ; Weening JJ; Florquin S
Kidney Int; 2003 Nov; 64(5):1845-53. PubMed ID: 14531820
[TBL] [Abstract][Full Text] [Related]
33. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
35. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
36. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
39. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
40. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases.
Garcia-Monco JC; Coleman JL; Benach JL
J Neuroimmunol; 2002 Aug; 129(1-2):216-23. PubMed ID: 12161038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
